Lupin Unit Plans 43.38% Acquisition in Philippines for USD 39.6 Million
Lupin Limited announced its subsidiary Nanomi B.V. will acquire 43.38% stake in Multicare Pharmaceuticals Philippines for up to USD 39.6 million, aiming for complete ownership by May 2026. The acquisition will increase Nanomi's shareholding from 56.28% to 99.66% in the Philippines-based pharmaceutical trading and distribution company.
*this image is generated using AI for illustrative purposes only.
Lupin Limited has announced a strategic acquisition to strengthen its presence in the Philippines pharmaceutical market. The company's wholly owned subsidiary, Nanomi B.V., plans to acquire minority shareholding in Multicare Pharmaceuticals Philippines, Inc. (MPPI), with the goal of taking full ownership by May 2026.
Transaction Structure
The acquisition involves the purchase of 11,794,497 shares from existing shareholders, representing 43.38% of MPPI's total outstanding paid-up shares. The transaction is structured as a cash consideration deal with a maximum value of USD 39.6 million or equivalent currency.
| Transaction Parameter: | Details |
|---|---|
| Shares to be Acquired: | 11,794,497 shares |
| Percentage Stake: | 43.38% |
| Maximum Consideration: | USD 39.6 million |
| Payment Method: | Cash consideration |
| Target Completion: | May 2026 |
| Strategic Goal: | Full ownership of MPPI |
About Multicare Pharmaceuticals Philippines
MPPI, incorporated on November 09, 2001, is headquartered in Philippines and operates in the pharmaceutical sector. The company is engaged in trading, importing, marketing, and distributing pharmaceutical products and medical devices. Currently, Nanomi holds 56.28% stake in MPPI, and this acquisition will increase its shareholding to 99.66%, positioning the company to achieve complete ownership.
Financial Performance Overview
MPPI has demonstrated business operations with revenue performance tracked over recent years:
| Financial Metrics: | Amount |
|---|---|
| Turnover (March 31, 2025): | PHP 2,096.6 million |
| Net Worth (March 31, 2025): | PHP 1,265.5 million |
| Year: | Turnover |
|---|---|
| FY 25: | PHP 2,096.6 million |
| FY 24: | PHP 2,351.2 million |
| FY 23: | PHP 1,744.7 million |
Strategic Benefits and Market Position
The acquisition is expected to deliver multiple strategic benefits for Lupin's operations in the Philippines market. The transaction will strengthen the company's market standing through its wholly owned subsidiary Nanomi and enable substantial integration of MPPI's operations. The move provides strategic flexibility, allowing Lupin to unify its emerging-market businesses and unlock long-term value in the region.
Regulatory Framework
The transaction falls under the purview of related party transactions, with requisite approval from the Audit Committee already obtained. The acquisition will be conducted on an arm's length basis, with a valuation report from Ernst & Young Merchant Banking Services LLP determining the fair value of MPPI shares. No governmental or regulatory approvals are required for this acquisition, and no promoter, promoter group, or group companies have any interest in the proposed transaction.
Historical Stock Returns for Lupin
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.02% | -3.11% | -1.19% | +14.80% | +16.32% | +121.47% |
How will Lupin's increased control over MPPI impact its competitive positioning against other multinational pharmaceutical companies in the Southeast Asian market?
What specific synergies and cost optimization opportunities might emerge from integrating MPPI's distribution network with Lupin's existing operations?
Could this acquisition serve as a blueprint for Lupin's expansion strategy into other emerging pharmaceutical markets in the Asia-Pacific region?
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
